Abeona Therapeutics Inc. (ABEO)
Largest Insider Buys in Sector
ABEO Stock Price History Chart
ABEO Stock Performance
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye …
Insider Activity of Abeona Therapeutics Inc.
Over the last 12 months, insiders at Abeona Therapeutics Inc. have bought $241,836 and sold $269,416 worth of Abeona Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Abeona Therapeutics Inc. have bought $226,097 and sold $1.07M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Seshadri Vishwas (Chief Executive Officer) — $119,800. Alland Leila (director) — $103,598. Vazzano Joseph Walter (Chief Financial Officer) — $35,218.
The last purchase of 11,000 shares for transaction amount of $51,799 was made by Alland Leila (director) on 2024‑05‑16.
List of Insider Buy and Sell Transactions, Abeona Therapeutics Inc.
| 2024-06-18 | Sale | director | 25,821 0.0635% | $4.51 | $116,453 | +29.07% | ||
| 2024-06-18 | Sale | director | 25,890 0.0637% | $4.51 | $116,764 | +29.07% | ||
| 2024-05-16 | director | 11,000 0.0286% | $4.71 | $51,799 | +20.78% | |||
| 2024-04-26 | director | 7,550 0.0265% | $3.28 | $24,764 | +69.33% | |||
| 2024-04-25 | Chief Executive Officer | 10,000 0.0343% | $3.20 | $32,000 | +72.10% | |||
| 2024-04-25 | Chief Financial Officer | 5,608 0.0189% | $3.14 | $17,609 | +72.10% | |||
| 2024-04-25 | SVP, General Counsel | 8,600 0.0299% | $3.24 | $27,864 | +72.10% | |||
| 2024-02-06 | Chief Executive Officer | 20,000 0.0784% | $4.39 | $87,800 | +36.98% | |||
| 2024-01-17 | Sale | director | 7,084 0.0285% | $5.11 | $36,199 | +12.20% | ||
| 2023-09-27 | Sale | director | 5,508 0.022% | $3.91 | $21,542 | +20.96% | ||
| 2023-09-27 | Sale | director | 6,330 0.0252% | $3.91 | $24,721 | +20.96% | ||
| 2023-09-27 | Sale | director | 7,246 0.0288% | $3.90 | $28,270 | +20.96% | ||
| 2023-09-27 | Sale | director | 8,330 0.0417% | $4.91 | $40,924 | +20.96% | ||
| 2023-09-27 | Sale | director | 6,316 0.0252% | $3.91 | $24,724 | +20.96% | ||
| 2023-09-27 | Chief Executive Officer | 20,000 0.083% | $4.07 | $81,400 | +20.96% | |||
| 2023-09-20 | Sale | director | 327 0.0014% | $3.90 | $1,275 | +25.53% | ||
| 2023-09-19 | Chief Financial Officer | 3,000 0.0122% | $3.82 | $11,458 | +25.59% | |||
| 2023-09-18 | SVP, General Counsel | 3,000 0.0125% | $3.80 | $11,400 | +29.70% | |||
| 2023-06-20 | Sale | director | 338 0.0039% | $4.45 | $1,504 | -3.52% | ||
| 2023-04-25 | Sale | director | 887 0.0105% | $3.25 | $2,883 | +31.60% |
Insider Historical Profitability
| Seshadri Vishwas | Chief Executive Officer | 538260 1.2382% | $5.68 | 3 | 0 | |
| Vazzano Joseph Walter | Chief Financial Officer | 233868 0.538% | $5.68 | 3 | 0 | <0.0001% |
| O'Malley Brendan M. | SVP, General Counsel | 188718 0.4341% | $5.68 | 4 | 5 | <0.0001% |
| Alland Leila | director | 82857 0.1906% | $5.68 | 1 | 1 | |
| Charles Faith L. | director | 78323 0.1802% | $5.68 | 1 | 1 |
Institutional Investor Ownership
| Adage Capital Partners Gp L L C | $23.56M | 7.93 | 3.25M | 0% | +$0 | 0.04 | |
| Nantahala Capital Management Llc | $16.75M | 5.64 | 2.31M | +2.68% | +$437,813.00 | 0.78 | |
| Millennium Management LLC | $14.4M | 4.85 | 1.99M | +40.03% | +$4.12M | 0.01 | |
| Western Standard Llc | $9.87M | 3.32 | 1.36M | +68.48% | +$4.01M | 13.34 | |
| The Vanguard Group | $7.99M | 2.69 | 1.1M | +0.07% | +$5,995.75 | <0.0001 |